多囊卵巢
无排卵
医学
不育
促排卵
妇科
二甲双胍
女性不育
产科
排卵
怀孕
胰岛素抵抗
胰岛素
内分泌学
激素
生物
遗传学
作者
Michael Costello,Marie Misso,Jennifer L. Wong,Roger Hart,Luk Rombauts,Angela Melder,Robert J. Norman,Helena Teede
标识
DOI:10.1111/j.1479-828x.2012.01448.x
摘要
Polycystic ovary syndrome ( PCOS ) is the most common cause of anovulatory infertility. Lifestyle change alone is considered the first‐line treatment for the management of infertile anovulatory PCOS women who are overweight or obese. First‐line medical ovulation induction therapy to improve fertility outcomes is clomiphene citrate, whilst gonadotrophins, laparoscopic ovarian surgery or possibly metformin are second line in clomiphene citrate‐resistant PCOS women. There is currently insufficient evidence to recommend aromatase inhibitors over that of clomiphene citrate in infertile anovulatory PCOS women in general or specifically in therapy naive or clomiphene citrate‐resistant PCOS women. IVF / ICSI treatment is recommended either as a third‐line treatment or in the presence of other infertility factors.
科研通智能强力驱动
Strongly Powered by AbleSci AI